Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: A meta-analysis of cohort studies

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Zhang, Tie Ning ^a   Gao, Shan Yan ^a   Shen, Zi Qi ^a   Li, Da ^a   Liu, Cai Xia ^a   Lv, Hai Chen ^b   Zhang, Yuan ^a   Gong, Ting Ting ^a   Xu, Xin ^a   Ji, Chao ^a   Wu, Qi Jun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

CARDIOVASCULAR MALFORMATION; CHEMICALLY INDUCED; DRUG INDUCED MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; META ANALYSIS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; RISK;

ABNORMALITIES, DRUG-INDUCED; CARDIOVASCULAR ABNORMALITIES; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 85013471839     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43085     Document Type: Article

References (70)

1. O'Keane, V. & Marsh, M. S. Depression during pregnancy. BMJ 334, 1003-5 (2007).
2. Ellfolk, M. & Malm, H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 30, 249-60 (2010).
3. Bennett, H. A., Einarson, A., Taddio, A., Koren, G. & Einarson, T. R. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103, 698-709 (2004).
4. Chatillon, O. & Even, C. Antepartum depression: prevalence, diagnosis and treatment. Encephale. 36, 443-51 (2010).
5. Field, T. et al. Chronic prenatal depression and neonatal outcome. Int J Neurosci 118, 95-103 (2008).
6. Field, T., Diego, M. & Hernandez-Reif, M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 29, 445-55 (2006).
7. Steer, R. A., Scholl, T. O., Hediger, M. L. & Fischer, R. L. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 45, 1093-9 (1992).
8. Ertel, K. A., Koenen, K. C., Rich-Edwards, J. W. & Gillman, M. W. Antenatal and postpartum depressive symptoms are differentially associated with early childhood weight and adiposity. Paediatr Perinat Epidemiol 24, 179-89 (2010).
9. Davalos, D. B., Yadon, C. A. & Tregellas, H. C. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health 15, 1-14 (2012).
10. Ververs, T. et al. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62, 863-70 (2006).
11. Andrade, S. E., et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198, 191-4 (2008).
12. Einarson, A. et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165, 749-52 (2008).
13. Einarson, T. R. & Einarson, A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14, 823-7 (2005).
14. Malm, H., Klaukka, T. & Neuvonen, P. J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106, 1289-96 (2005).
15. Wen, S. W. et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 194, 961-6 (2006).
16. Berard, A. et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80, 18-27 (2007).
17. Cole, J. A., Ephross, S. A., Cosmatos, I. S. & Walker, A. M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16, 1075-85 (2007).
18. Cooper, W. O., Willy, M. E., Pont, S. J. & Ray, W. A. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196, 541-4 (2007).
19. Pedersen, L. H., Henriksen, T. B., Vestergaard, M., Olsen, J. & Bech, B. H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339, b3569 (2009).
20. Merlob, P. et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 85, 837-41 (2009).
21. Colvin, L., Slack-Smith, L., Stanley, F. J. & Bower, C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 91, 142-52 (2011).
22. Oberlander, T. F. et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83, 68-76 (2008).
23. Louik, C., Lin, A. E., Werler, M. M., Hernandez-Diaz, S. & Mitchell, A. A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356, 2675-83 (2007).
24. Davis, R. L. et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16, 1086-94 (2007).
25. Rahimi, R., Nikfar, S. & Abdollahi, M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 22, 571-5 (2006).
26. Nikfar, S., Rahimi, R., Hendoiee, N. & Abdollahi, M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis. DARU 20, 75 (2012).
27. Wang, S. et al. Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc 4, e001681 (2015).
28. Reefhuis, J., Devine, O., Friedman, J. M., Louik, C. & Honein, M. A. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 351, h3190 (2015).
29. Grigoriadis, S. et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 74, e293-308 (2013).
30. Furu, K. et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 350, h2235 (2015).
31. Berard, A., Zhao, J. P. & Sheehy, O. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol 212, 791-5 (2015).
32. Ban, L. et al. Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study. BJOG 121, 1471-81 (2014).
33. Huybrechts, K. F., Hernandez-Diaz, S. & Avorn, J. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 371, 1168-9 (2014).
34. Knudsen, T. M., Hansen, A. V., Garne, E. & Andersen, A. M. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth 14, 333 (2014).
35. Vasilakis-Scaramozza, C., Aschengrau, A., Cabral, H. & Jick, S. S. Antidepressant use during early pregnancy and the risk of congenital anomalies. Pharmacotherapy 33, 693-700 (2013).
36. Margulis, A. V. et al. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 22, 942-51 (2013).
37. Malm, H., Artama, M. & Gissler, M. & Ritvanen. Selective serotonin reuptake inhibitors and risk for major congenital anormalies. Obstet Gynecol 118, 111-20 (2011).
38. Nordeng, H. et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 32, 186-94 (2012).
39. Jimenez-Solem, E. et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2, e001148 (2012).
40. Kornum, J. B., Nielsen, R. B., Pedersen, L., Mortensen, P. B. & Norgaard, M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2, 29-36 (2010).
41. Davis, R. L. et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidem DR S 16, 1086-94 (2007).
42. Kallen, B. A. & Otterblad, O. P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79, 301-8 (2007).
43. Kulin, N. A. et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279, 609-10 (1998).
44. Wells, G. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa Hospital Research Institute. Available from: http://www. ohri. ca/programs/clinical-epidemiology/oxford. asp. (Data of access: 15/January/2017) (2013).
45. Laurent, L. et al. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. Birth Defects Res A Clin Mol Teratol 106, 1044-55 (2016).
46. Yavarone, M. S., Shuey, D. L., Tamir, H., Sadler, T. W. & Lauder, J. M. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47, 573-84 (1993).
47. Sari, Y. & Zhou, F. C. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 21, 417-24 (2003).
48. Buskohl, P. R., Sun, M. L., Thompson, R. P. & Butcher, J. T. Serotonin Potentiates Transforming Growth Factor-beta3 Induced Biomechanical Remodeling in Avian Embryonic Atrioventricular Valves. PLoS One 7, e42527 (2012).
49. Lage, K. et al. Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci USA 109, 14035-40 (2012).
50. Bar-Oz, B. et al. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther 29, 918-26 (2007).
51. Brite, J., Laughon, S. K., Troendle, J. & Mills, J. Maternal overweight and obesity and risk of congenital heart defects in offspring. Int J Obes (Lond) 38, 878-82 (2014).
52. Yang, J., Carmichael, S. L., Canfield, M., Song, J. & Shaw, G. M. Socioeconomic status in relation to selected birth defects in a large multicentered US case-control study. Am J Epidemiol 167, 145-54 (2008).
53. Rivera, H. M., Christiansen, K. J. & Sullivan, E. L. The role of maternal obesity in the risk of neuropsychiatric disorders. Front Neurosci 9, 194 (2015).
54. Mitchell, K. J. & Schwarzwald, C. C. Echocardiography for the Assessment of Congenital Heart Defects in Calves. Vet Clin North Am Food Anim Pract 32, 37-54 (2016).
55. Moher, D. et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM Statement. Rev Esp Salud Publica 74, 107-18 (2000).
56. Gong, T. T., Wu, Q. J., Vogtmann, E., Lin, B. & Wang, Y. L. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 132, 2894-900 (2013).
57. Wu, Q. J. et al. Consumption of fruit and vegetables reduces risk of pancreatic cancer: evidence from epidemiological studies. Eur J Cancer Prev 25, 196-205 (2016).
58. Wu, Q. J. et al. Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24, 1079-87 (2013).
59. Shen, Z. Q. et al. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br J Clin Pharmacol, doi: 10. 1111/bcp. 13161 (2016).
60. Hamling, J., Lee, P., Weitkunat, R. & Ambuhl, M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27, 954-70 (2008).
61. Cui, H., Gong, T. T., Liu, C. X. & Wu, Q. J. Associations between Passive Maternal Smoking during Pregnancy and Preterm Birth: Evidence from a Meta-Analysis of Observational Studies. PLoS One 11, e147848 (2016).
62. Luan, N. N. et al. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr 98, 1020-31 (2013).
63. Gong, T. T., Wu, Q. J., Wang, Y. L. & Ma, X. X. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: Evidence from a meta-analysis of epidemiologic studies. Int J Cancer 137, 1967-78 (2015).
64. Chen, J., Gong, T. T. & Wu, Q. J. Parity and gastric cancer risk: a systematic review and dose-response meta-analysis of prospective cohort studies. Sci Rep 6, 18766 (2016).
65. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-88 (1986).
66. Wu, Q. J., Yang, Y., Wang, J., Han, L. H. & Xiang, Y. B. Cruciferous vegetable consumption and gastric cancer risk: a meta-analysis of epidemiological studies. Cancer Sci 104, 1067-73 (2013).
67. Jiang, L., Hou, R., Gong, T. T. & Wu, Q. J. Dietary fat intake and endometrial cancer risk: dose-response meta-analysis of epidemiological studies. Sci Rep 5, 16693 (2015).
68. Wu, Q. J., Gong, T. T. & Wang, Y. Z. Dietary fatty acids intake and endometrial cancer risk: a dose-response meta-analysis of epidemiological studies. Oncotarget 6, 36081-97 (2015).
69. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-34 (1997).
70. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-101 (1994).